The company is anticipating completion of commissioning and qualification activities by summer 2021
Nexus Pharmaceuticals has received authorisation to occupy its pharmaceutical manufacturing facility from the Village of Pleasant Prairie, Wisconsin.
The company, which specialises in developing processes to manufacture specialty and generic injectables drugs, first announced plans in 2019 to build Project Tomorrow, a sterile injectable manufacturing facility to support the production and supply of injectable drugs in various therapeutic areas including anaesthesiology, oncology, cardiology, and neurology.
Project Tomorrow, in which Nexus plans to invest $250 m, is projected to be completed in three phases within the next ten years. Phase one, which began in August 2019 and includes a three-story manufacturing facility with an isolator filling system and a large capacity lyophiliser, is nearing completion, the company says. Nexus and the Village of Pleasant Prairie partnered with Integrated Project Services and Turner Construction on the design and construction of the 84,000 sqft structure. Phases two and three will include cytotoxic and highly potent manufacturing suites, increased warehousing, and expanded secondary packaging.
“We at Nexus Pharmaceuticals are very pleased with the issuance of the occupancy authorization for the site,” said President and CEO, Mariam S Darsot. “This is a critical milestone and brings us one step closer to manufacturing critical and essential medications in the United States. I would like to thank all of our vendors and especially our Project Tomorrow team here at Nexus for their tireless efforts in reaching this tremendous juncture.”
Now the staff are able to relocate into the manufacturing facility, Nexus anticipates a forthcoming inspection by the FDA, completing the four-year journey from concept to completion. Pending approval, commercial pharmaceutical production is hoped to begin as early as 2022.
Meanwhile, Nexus is continuing its commitment to supporting the Wisconsin economy by creating over 400 new local jobs long-term. The company anticipates completing phase one of hiring and operations by the beginning of the third quarter of 2021, which will create 77 jobs in the fields of high-tech manufacturing and scientific research. Phase two of hiring is expected to commence in 2022.